Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102.
Latest Ratings for URGN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 2022 | HC Wainwright & Co. | Maintains | Buy | |
| Apr 2021 | HC Wainwright & Co. | Maintains | Buy | |
| Apr 2020 | Oppenheimer | Maintains | Outperform |
